Leukemia diagnosis and monitoring rely increasingly on high-throughput image data, yet conventional clustering methods lack the flexibility to accommodate evolving cellular patterns and quantify uncertainty in real time. We introduce Adaptive and Dynamic Neuro-Fuzzy Clustering, a novel streaming-capable framework that combines Convolutional Neural Network-based feature extraction with an online fuzzy clustering engine. ADNF initializes soft partitions via Fuzzy C-Means, then continuously updates micro-cluster centers, densities, and fuzziness parameters using a Fuzzy Temporal Index (FTI) that measures entropy evolution. A topology refinement stage performs density-weighted merging and entropy-guided splitting to guard against over- and under-segmentation. On the C-NMC leukemia microscopy dataset, our tool achieves a silhouette score of 0.51, demonstrating superior cohesion and separation over static baselines. The method's adaptive uncertainty modeling and label-free operation hold immediate potential for integration within the INFANT pediatric oncology network, enabling scalable, up-to-date support for personalized leukemia management.

Things to Do in L.A. Tap to enable a layout that focuses on the article. 'I just wanted to help.' Father turns to 9-year-old son for lifesaving stem cell donation Stephen Mondek became what Cedars-Sinai Medical Center believes is its youngest known stem cell donor. His father was dying of acute myeloid leukemia, a cancer that affects blood-forming cells in the bone marrow, and needed a donation to rebuild his immune system. This is read by an automated voice. Please report any issues or inconsistencies here .

The dynamic environment of laboratories and clinics, with streams of data arriving on a daily basis, requires regular updates of trained machine learning models for consistent performance. Continual learning is supposed to help train models without catastrophic forgetting. However, state-of-the-art methods are ineffective for multiple instance learning (MIL), which is often used in single-cell-based hematologic disease diagnosis (e.g., leukemia detection). Here, we propose the first continual learning method tailored specifically to MIL. Our method is rehearsal-based over a selection of single instances from various bags. We use a combination of the instance attention score and distance from the bag mean and class mean vectors to carefully select which samples and instances to store in exemplary sets from previous tasks, preserving the diversity of the data. Using the real-world input of one month of data from a leukemia laboratory, we study the effectiveness of our approach in a class incremental scenario, comparing it to well-known continual learning methods. We show that our method considerably outperforms state-of-the-art methods, providing the first continual learning approach for MIL. This enables the adaptation of models to shifting data distributions over time, such as those caused by changes in disease occurrence or underlying genetic alterations.

The complexities inherent to leukemia, multifaceted cancer affecting white blood cells, pose considerable diagnostic and treatment challenges, primarily due to reliance on laborious morphological analyses and expert judgment that are susceptible to errors. Addressing these challenges, this study presents a refined, comprehensive strategy leveraging advanced deep-learning techniques for the classification of leukemia subtypes. We commence by developing a hierarchical label taxonomy, paving the way for differentiating between various subtypes of leukemia. The research further introduces a novel hierarchical approach inspired by clinical procedures capable of accurately classifying diverse types of leukemia alongside reactive and healthy cells. An integral part of this study involves a meticulous examination of the performance of Convolutional Neural Networks (CNNs) and Vision Transformers (ViTs) as classifiers. The proposed method exhibits an impressive success rate, achieving approximately 90\% accuracy across all leukemia subtypes, as substantiated by our experimental results. A visual representation of the experimental findings is provided to enhance the model's explainability and aid in understanding the classification process.

Thousands of individuals succumb annually to leukemia alone. As artificial intelligence-driven technologies continue to evolve and advance, the question of their applicability and reliability remains unresolved. This study aims to utilize image processing and deep learning methodologies to achieve state-of-the-art results for the detection of Acute Lymphoblastic Leukemia (ALL) using data that best represents real-world scenarios. ALL is one of several types of blood cancer, and it is an aggressive form of leukemia. In this investigation, we examine the most recent advancements in ALL detection, as well as the latest iteration of the YOLO series and its performance. We address the question of whether white blood cells are malignant or benign. Additionally, the proposed models can identify different ALL stages, including early stages. Furthermore, these models can detect hematogones despite their frequent misclassification as ALL. By utilizing advanced deep learning models, namely, YOLOv8, YOLOv11, ResNet50 and Inception-ResNet-v2, the study achieves accuracy rates as high as 99.7%, demonstrating the effectiveness of these algorithms across multiple datasets and various real-world situations.

A mutation in the DNA of a single cell that compromises its function initiates leukemia,leading to the overproduction of immature white blood cells that encroach upon the space required for the generation of healthy blood cells.Leukemia is treatable if identified in its initial stages. However,its diagnosis is both arduous and time consuming. This study proposes a novel approach for diagnosing leukemia across four stages Benign,Early,Pre,and Pro using deep learning techniques.We employed two Convolutional Neural Network (CNN) models as MobileNetV2 with an altered head and a custom model. The custom model consists of multiple convolutional layers,each paired with corresponding max pooling layers.We utilized MobileNetV2 with ImageNet weights,adjusting the head to integrate the final results.The dataset used is the publicly available "Acute Lymphoblastic Leukemia (ALL) Image Dataset", and we applied the Synthetic Minority Oversampling Technique (SMOTE) to augment and balance the training dataset.The custom model achieved an accuracy of 98.6%, while MobileNetV2 attained a superior accuracy of 99.69%. The pretrained model showed promising results,indicating an increased likelihood of real-world application.

Machine-learning (ML) models in flow cytometry have the potential to reduce error rates, increase reproducibility, and boost the efficiency of clinical labs. While numerous ML models for flow cytometry data have been proposed, few studies have described the clinical deployment of such models. Realizing the potential gains of ML models in clinical labs requires not only an accurate model, but infrastructure for automated inference, error detection, analytics and monitoring, and structured data extraction. Here, we describe an ML model for detection of Acute Myeloid Leukemia (AML), along with the infrastructure supporting clinical implementation. Our infrastructure leverages the resilience and scalability of the cloud for model inference, a Kubernetes-based workflow system that provides model reproducibility and resource management, and a system for extracting structured diagnoses from full-text reports. We also describe our model monitoring and visualization platform, an essential element for ensuring continued model accuracy. Finally, we present a post-deployment analysis of impacts on turn-around time and compare production accuracy to the original validation statistics.

Representing and quantifying Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML), a type of cancer that affects the blood and bone marrow, is essential in the prognosis and follow-up of AML patients. As traditional cytological analysis cannot detect leukemia cells below 5\%, the analysis of flow cytometry dataset is expected to provide more reliable results. In this paper, we explore statistical learning methods based on optimal transport (OT) to achieve a relevant low-dimensional representation of multi-patient flow cytometry measurements (FCM) datasets considered as high-dimensional probability distributions. Using the framework of OT, we justify the use of the K-means algorithm for dimensionality reduction of multiple large-scale point clouds through mean measure quantization by merging all the data into a single point cloud. After this quantization step, the visualization of the intra and inter-patients FCM variability is carried out by embedding low-dimensional quantized probability measures into a linear space using either Wasserstein Principal Component Analysis (PCA) through linearized OT or log-ratio PCA of compositional data. Using a publicly available FCM dataset and a FCM dataset from Bordeaux University Hospital, we demonstrate the benefits of our approach over the popular kernel mean embedding technique for statistical learning from multiple high-dimensional probability distributions. We also highlight the usefulness of our methodology for low-dimensional projection and clustering patient measurements according to their level of MRD in AML from FCM. In particular, our OT-based approach allows a relevant and informative two-dimensional representation of the results of the FlowSom algorithm, a state-of-the-art method for the detection of MRD in AML using multi-patient FCM.

Acute Leukemia is the most common hematologic malignancy in children and adolescents. A key methodology in the diagnostic evaluation of this malignancy is immunophenotyping based on Multiparameter Flow Cytometry (FCM). However, this approach is manual, and thus time-consuming and subjective. To alleviate this situation, we propose in this paper the FCM-Former, a machine learning, self-attention based FCM-diagnostic tool, automating the immunophenotyping assessment in Childhood Acute Leukemia. The FCM-Former is trained in a supervised manner, by directly using flow cytometric data. Our FCM-Former achieves an accuracy of 96.5% assigning lineage to each sample among 960 cases of either acute B-cell, T-cell lymphoblastic, and acute myeloid leukemia (B-ALL, T-ALL, AML). To the best of our knowledge, the FCM-Former is the first work that automates the immunophenotyping assessment with FCM data in diagnosing pediatric Acute Leukemia.

Single-cell datasets often lack individual cell labels, making it challenging to identify cells associated with disease. To address this, we introduce Mixture Modeling for Multiple Instance Learning (MMIL), an expectation maximization method that enables the training and calibration of cell-level classifiers using patient-level labels. Our approach can be used to train e.g. lasso logistic regression models, gradient boosted trees, and neural networks. When applied to clinically-annotated, primary patient samples in Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL), our method accurately identifies cancer cells, generalizes across tissues and treatment timepoints, and selects biologically relevant features. In addition, MMIL is capable of incorporating cell labels into model training when they are known, providing a powerful framework for leveraging both labeled and unlabeled data simultaneously. Mixture Modeling for MIL offers a novel approach for cell classification, with significant potential to advance disease understanding and management, especially in scenarios with unknown gold-standard labels and high dimensionality.